Issue 9/2012

  • Is gene therapy finally coming into its own?

    In this issue:


    Is gene therapy finally coming into its own?

    After a balancing act that went down to the wire with regulators – and left its predecessor company bankrupt – uniQure biotherapies now looks set to become the first pharma company to gain approval for a gene therapy in Europe. the concept of ‘curing’ rare inherited diseases by altering a patient’s genome in key cells has been around for decades. But disastrous, highly-publicised failures to harness the technology in the past frightened off developers and patients alike. Now that looks set to change.

Volume 2014

Volume 2013

Volume 2012

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/9/pos/1.html?sort=asc&cHash=2aa63e7a3c47f54d547eeaaa494e591b

Kurszettel

Alle Kurse

TOP

  • 4SC0.84 EUR0.00%
  • ACTELION100.80 CHF0.00%
  • ADDEX3.28 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.84 EUR0.00%
  • ACTELION100.80 CHF0.00%

TOP

  • CYTOS0.36 CHF56.5%
  • FORMYCON15.48 EUR53.6%
  • ADDEX3.28 CHF41.4%

FLOP

  • BIOFRONTERA1.93 EUR-16.1%
  • ACTELION100.80 CHF-13.3%
  • MOLOGEN5.75 EUR-9.4%

TOP

  • SANTHERA105.00 CHF2544.8%
  • WILEX1.96 EUR168.5%
  • FORMYCON15.48 EUR103.7%

FLOP

  • CYTOS0.36 CHF-90.1%
  • 4SC0.84 EUR-49.7%
  • MOLOGEN5.75 EUR-49.7%

No liability assumed, Date: 31.01.2015